Healthcare provider profile · identity verified

Eric E Goldberg, DO

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · DESTIN, FL · NPI 1679524946

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Eric E Goldberg, DO received $118,233.47 in general payments during 2025 across 227 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 68.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 18 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$118,233.47

227 reported records · 16 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$80,831.35	68.4%	155	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$33,548.43	28.4%	32	2025
MDD US Operations, LLC	Unresolved — no canonical attribution shown	$2,693.35	2.3%	4	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$252.64	0.2%	9	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$151.28	0.1%	4	2025
Boston Scientific Corporation	Unresolved — no canonical attribution shown	$149.72	0.1%	1	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$145.16	0.1%	7	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$121.24	0.1%	1	2025
JAZZ PHARMACEUTICALS INC.	Unresolved — no canonical attribution shown	$118.88	0.1%	4	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$40.61	0.0%	2	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$40.16	0.0%	2	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$39.41	0.0%	2	2025
Avadel CNS Pharmaceuticals, LLC	Unresolved — no canonical attribution shown	$33.40	0.0%	1	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$24.67	0.0%	1	2025
Corium, LLC	Unresolved — no canonical attribution shown	$23.15	0.0%	1	2025
IDORSIA PHARMACEUTICALS US INC	Unresolved — no canonical attribution shown	$20.02	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$64,680.00	20
Honoraria	$31,175.00	13
Travel and Lodging	$11,109.81	55
Food and Beverage	$5,988.66	137
Consulting Fee	$5,280.00	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$80,831.35	155	2025
Source payment records 2025-01-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.90 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.12 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.00 · Open Payments source 2025-03-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.81 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.60 · Open Payments source 2025-05-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.47 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.58 · Open Payments source 2025-06-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-06-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.67 · Open Payments source 2025-06-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.48 · Open Payments source 2025-06-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.50 · Open Payments source 2025-06-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $153.03 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-07-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.07 · Open Payments source 2025-07-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.73 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $197.42 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.00 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $431.90 · Open Payments source 2025-07-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.20 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.95 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $225.87 · Open Payments source 2025-08-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.65 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-08-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.44 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $238.26 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $103.88 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.71 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $609.00 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.83 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $42.98 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.35 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.93 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.08 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.84 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $148.40 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.66 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.00 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-09-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.81 · Open Payments source 2025-09-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.74 · Open Payments source 2025-09-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $42.16 · Open Payments source 2025-09-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $72.80 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $35.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $207.00 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.25 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.93 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $156.38 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $218.57 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.94 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $76.76 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $366.80 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.21 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.46 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $50.54 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.45 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.80 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.42 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $190.40 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.13 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.42 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.87 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $109.84 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $183.68 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $118.24 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $223.88 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $162.07 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $201.38 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.60 · Open Payments source 2025-11-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.29 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.87 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.35 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.35 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $35.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $392.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $392.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.21 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $93.26 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.47 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.42 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.34 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.34 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $452.20 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.88 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.26 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.93 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.45 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $140.70 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $207.90 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.45 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.55 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.60 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.20 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.78 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $37.98 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.24 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.37 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $308.70 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.40 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.68 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.88 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.23 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $214.90 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.12 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-12-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.43 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.00 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.85 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.68 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $198.10 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.84 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.00 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $71.40 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $50.00 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.93 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.33 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $50.40 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $50.00 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.46 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $219.22 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source
Qelbree Normalized: qelbree	Drug	MDD US Operations, LLC, Supernus Pharmaceuticals, Inc.	$36,241.78	36	2025
Source payment records 2025-05-12 · Supernus Pharmaceuticals, Inc. · $63.60 · Open Payments source 2025-05-12 · Supernus Pharmaceuticals, Inc. · $1,125.00 · Open Payments source 2025-08-05 · Supernus Pharmaceuticals, Inc. · $19.40 · Open Payments source 2025-08-05 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-08-05 · Supernus Pharmaceuticals, Inc. · $713.42 · Open Payments source 2025-08-05 · Supernus Pharmaceuticals, Inc. · $103.37 · Open Payments source 2025-08-19 · MDD US Operations, LLC · $117.88 · Open Payments source 2025-08-19 · MDD US Operations, LLC · $2,500.00 · Open Payments source 2025-08-19 · MDD US Operations, LLC · $58.80 · Open Payments source 2025-08-19 · MDD US Operations, LLC · $16.67 · Open Payments source 2025-08-20 · Supernus Pharmaceuticals, Inc. · $1,184.00 · Open Payments source 2025-08-20 · Supernus Pharmaceuticals, Inc. · $125.16 · Open Payments source 2025-08-20 · Supernus Pharmaceuticals, Inc. · $22.61 · Open Payments source 2025-08-20 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-08-20 · Supernus Pharmaceuticals, Inc. · $115.69 · Open Payments source 2025-08-20 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-08-27 · Supernus Pharmaceuticals, Inc. · $5.87 · Open Payments source 2025-10-02 · Supernus Pharmaceuticals, Inc. · $1,350.00 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $598.47 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $148.86 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $23.99 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $692.47 · Open Payments source 2025-10-14 · Supernus Pharmaceuticals, Inc. · $73.06 · Open Payments source 2025-10-14 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-10-14 · Supernus Pharmaceuticals, Inc. · $714.98 · Open Payments source 2025-10-14 · Supernus Pharmaceuticals, Inc. · $67.97 · Open Payments source 2025-11-05 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-11-05 · Supernus Pharmaceuticals, Inc. · $5,200.00 · Open Payments source 2025-11-05 · Supernus Pharmaceuticals, Inc. · $27.12 · Open Payments source 2025-11-06 · Supernus Pharmaceuticals, Inc. · $124.99 · Open Payments source 2025-11-06 · Supernus Pharmaceuticals, Inc. · $1,000.00 · Open Payments source 2025-11-06 · Supernus Pharmaceuticals, Inc. · $24.34 · Open Payments source 2025-11-06 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-11-06 · Supernus Pharmaceuticals, Inc. · $24.06 · Open Payments source 2025-11-06 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$238.20	8	2025
Source payment records 2025-01-09 · ABBVIE INC. · $16.58 · Open Payments source 2025-02-27 · ABBVIE INC. · $17.58 · Open Payments source 2025-02-27 · ABBVIE INC. · $125.00 · Open Payments source 2025-06-06 · ABBVIE INC. · $5.93 · Open Payments source 2025-07-10 · ABBVIE INC. · $16.70 · Open Payments source 2025-09-24 · ABBVIE INC. · $17.94 · Open Payments source 2025-11-12 · ABBVIE INC. · $20.47 · Open Payments source 2025-12-04 · ABBVIE INC. · $18.00 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$151.28	4	2025
Source payment records 2025-09-11 · Vanda Pharmaceuticals Inc. · $6.65 · Open Payments source 2025-09-25 · Vanda Pharmaceuticals Inc. · $121.24 · Open Payments source 2025-10-15 · Vanda Pharmaceuticals Inc. · $15.26 · Open Payments source 2025-10-29 · Vanda Pharmaceuticals Inc. · $8.13 · Open Payments source
WATCHMAN FLX Normalized: watchman flx	Device	Boston Scientific Corporation	$149.72	1	2025
Source payment records 2025-02-18 · Boston Scientific Corporation · $149.72 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$145.16	7	2025
Source payment records 2025-03-07 · Axsome Therapeutics, Inc. · $24.22 · Open Payments source 2025-04-17 · Axsome Therapeutics, Inc. · $33.77 · Open Payments source 2025-05-23 · Axsome Therapeutics, Inc. · $15.47 · Open Payments source 2025-07-02 · Axsome Therapeutics, Inc. · $12.67 · Open Payments source 2025-08-06 · Axsome Therapeutics, Inc. · $27.67 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $5.67 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $25.69 · Open Payments source
TEZSPIRE Normalized: tezspire	Biological	AstraZeneca Pharmaceuticals LP	$121.24	1	2025
Source payment records 2025-09-18 · AstraZeneca Pharmaceuticals LP · $121.24 · Open Payments source
XYWAV Normalized: xywav	Drug	JAZZ PHARMACEUTICALS INC.	$118.88	4	2025
Source payment records 2025-03-06 · JAZZ PHARMACEUTICALS INC. · $22.66 · Open Payments source 2025-04-25 · JAZZ PHARMACEUTICALS INC. · $29.75 · Open Payments source 2025-06-16 · JAZZ PHARMACEUTICALS INC. · $34.14 · Open Payments source 2025-09-11 · JAZZ PHARMACEUTICALS INC. · $32.33 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$80.02	4	2025
Source payment records 2025-01-16 · Otsuka America Pharmaceutical, Inc. · $15.46 · Open Payments source 2025-02-13 · Lundbeck LLC · $16.77 · Open Payments source 2025-06-04 · Otsuka America Pharmaceutical, Inc. · $23.95 · Open Payments source 2025-06-25 · Lundbeck LLC · $23.84 · Open Payments source
LUMRYZ Normalized: lumryz	Drug	Avadel CNS Pharmaceuticals, LLC	$33.40	1	2025
Source payment records 2025-12-02 · Avadel CNS Pharmaceuticals, LLC · $33.40 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$24.67	1	2025
Source payment records 2025-10-02 · Alkermes, Inc. · $24.67 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$23.15	1	2025
Source payment records 2025-09-23 · Corium, LLC · $23.15 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$22.47	1	2025
Source payment records 2025-05-08 · Teva Pharmaceuticals USA, Inc. · $22.47 · Open Payments source
Quviviq Normalized: quviviq	Drug	IDORSIA PHARMACEUTICALS US INC	$20.02	1	2025
Source payment records 2025-05-14 · IDORSIA PHARMACEUTICALS US INC · $20.02 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$17.69	1	2025
Source payment records 2025-02-21 · Teva Pharmaceuticals USA, Inc. · $17.69 · Open Payments source
QULIPTA Normalized: qulipta	Drug	ABBVIE INC.	$14.44	1	2025
Source payment records 2025-01-06 · ABBVIE INC. · $14.44 · Open Payments source
UBRELVY Normalized: ubrelvy	Drug	ABBVIE INC.	$14.44	1	2025
Source payment records 2025-01-06 · ABBVIE INC. · $14.44 · Open Payments source
HETLIOZ Normalized: hetlioz	Drug	Vanda Pharmaceuticals Inc.	$8.13	1	2025
Source payment records 2025-10-29 · Vanda Pharmaceuticals Inc. · $8.13 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	56	suppressed
Alprazolam	Alprazolam	39	11
Lamotrigine	Lamotrigine	36	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	31	suppressed
Lurasidone Hcl	Lurasidone Hcl	22	suppressed
Clonazepam	Clonazepam	18	13
Vilazodone Hcl	Vilazodone Hcl	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Trazodone Hcl	Trazodone Hcl	13	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$118,233.47 · 227 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, FANAPT, HETLIOZ, LUMRYZ, LYBALVI, QULIPTA, Qelbree, Quviviq, REXULTI, TEZSPIRE, UBRELVY, UZEDY, VRAYLAR, WATCHMAN FLX, XYWAV	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error